Medtronic Reveals Plans For Next-Generation ‘Drug-Filled’ Stent

The firm characterizes the early-stage technology as its answer to Abbott’s bioabsorbable vascular scaffold and Boston Scientific’s bioabsorbable polymer coronary stents.

Medtronic PLC is developing a new stent technology and the idea is to turn the traditional drug-eluting platform inside out, literally.

Currently at a “very early stage of development,” the device would be a drug-filled coronary stent incorporating a polymer-free design,...

More from Clinical Trials

More from R&D